One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Zoetis stock now clears that threshold, with a jump from 78 to 81 Friday.
As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.
IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the best-performing stocks often have an RS Rating north of 80 in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
Is Zoetis Stock A Buy?
Zoetis stock is not currently near a potential buy zone. See if the stock goes on to form a chart pattern that could launch a new move. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Top and bottom line growth moved higher last quarter. Earnings were up 15%, compared to -3% in the prior report. Revenue increased from 1% to 4%.
Zoetis stock earns the No. 3 rank among its peers in the Medical-Ethical Drugs industry group. Zoetis and Takeda Pharmaceutical ADR are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
